Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 18/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652825 | 0.91 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5656470 | 0.88 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5667817 | 0.88 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4886755 | 0.85 | CYP3A4 (0.82) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4662488 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4161190 | 0.78 | CYP3A4 (0.80) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4180262 | 0.77 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4170085 | 0.76 | CYP3A4 (0.83) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6216038 | 0.75 | CYP3A4 (0.78) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL29405170 | 0.75 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167427-A1 | 1,2,4-Triazolo[4,3-a]pyridines useful in the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1718646-A1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINES USEFUL IN THE TREATMENT OF GASTROINTESTINAL DISORDERS | Altana Pharma AG (DE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005077947-A1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINES USEFUL IN THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167427-A1 | 1,2,4-Triazolo[4,3-a]pyridines useful in the treatment of gastrointestinal disorders | GIPR, SLC10A2, GRPR | CYP3A4 58/4885CYP2C9 245/4885CYP2D6 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.